Header Logo

Connection

Ebrahim Variava to Cohort Studies

This is a "connection" page, showing publications Ebrahim Variava has written about Cohort Studies.
Connection Strength

0,264
  1. Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity. Lancet Respir Med. 2020 04; 8(4):326-328.
    View in: PubMed
    Score: 0,139
  2. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021 Jan 04; 21(1):5.
    View in: PubMed
    Score: 0,037
  3. Hospitalization and post-discharge care in South Africa: A critical event in the continuum of care. PLoS One. 2018; 13(12):e0208429.
    View in: PubMed
    Score: 0,032
  4. Influenza Viral Shedding in a Prospective Cohort of HIV-Infected and Uninfected Children and Adults in 2 Provinces of South Africa, 2012-2014. J Infect Dis. 2018 09 08; 218(8):1228-1237.
    View in: PubMed
    Score: 0,031
  5. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015 Aug; 19(8):979-85.
    View in: PubMed
    Score: 0,025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.